159 related articles for article (PubMed ID: 11880373)
21. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
[TBL] [Abstract][Full Text] [Related]
22. Effects of the N-terminal sequence of ACE on the properties of its C-domain.
Marcic B; Deddish PA; Jackman HL; Erdös EG; Tan F
Hypertension; 2000 Jul; 36(1):116-21. PubMed ID: 10904022
[TBL] [Abstract][Full Text] [Related]
23. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level.
Hecker M; Pörsti I; Bara AT; Busse R
Br J Pharmacol; 1994 Jan; 111(1):238-44. PubMed ID: 8012702
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.
Erdös EG; Tan F; Skidgel RA
Hypertension; 2010 Feb; 55(2):214-20. PubMed ID: 20065150
[TBL] [Abstract][Full Text] [Related]
25. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
Enseleit F; Hürlimann D; Lüscher TF
J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
[TBL] [Abstract][Full Text] [Related]
26. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.
Silvestre JS; Bergaya S; Tamarat R; Duriez M; Boulanger CM; Levy BI
Circ Res; 2001 Oct; 89(8):678-83. PubMed ID: 11597990
[TBL] [Abstract][Full Text] [Related]
27. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
Busse R; Hecker M
Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
[TBL] [Abstract][Full Text] [Related]
28. Enalaprilat-mediated activation of kinin b(1) receptors and vasodilation in the rat isolated perfused kidney.
Bautista-Pérez R; Arellano A; Franco M; Osorio H; Coronel I
Pharmacology; 2011; 87(3-4):195-203. PubMed ID: 21430409
[TBL] [Abstract][Full Text] [Related]
29. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
[TBL] [Abstract][Full Text] [Related]
30. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.
Deddish PA; Marcic B; Jackman HL; Wang HZ; Skidgel RA; Erdös EG
Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
[TBL] [Abstract][Full Text] [Related]
32. An in vitro reconstitution system to address the mechanism of the vascular expression of the bradykinin B₁ receptor in response to angiotensin converting enzyme inhibition.
Roy C; Marceau E; Gera L; Marceau F
Vascul Pharmacol; 2012 Aug; 57(1):15-23. PubMed ID: 21986309
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE.
Campbell DJ
Clin Exp Pharmacol Physiol; 1995 Dec; 22(12):903-11. PubMed ID: 8846511
[TBL] [Abstract][Full Text] [Related]
34. The haemodynamic effects of two angiotensin converting enzyme inhibitors, enalaprilat and zofenoprilat, in the rat: evidence for the involvement of bradykinin.
Tio RA; Heiligers JP; de Langen CD; van Gilst WH; König W; Saxena PR; Wesseling H
J Hypertens Suppl; 1989 Dec; 7(6):S296-7. PubMed ID: 2561143
[TBL] [Abstract][Full Text] [Related]
35. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries.
Auch-Schwelk W; Bossaller C; Claus M; Graf K; Gräfe M; Fleck E
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S62-7. PubMed ID: 1282632
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers.
Chalon S; Moreno H; Hoffman BB; Blaschke TF
Clin Pharmacol Ther; 1999 Mar; 65(3):295-303. PubMed ID: 10096262
[TBL] [Abstract][Full Text] [Related]
37. Lack of direct interaction between enalaprilat and the kinin B1 receptors.
Morissette G; Couture JP; Désormeaux A; Adam A; Marceau F
Peptides; 2008 Apr; 29(4):606-12. PubMed ID: 18201802
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors.
Mombouli JV; Illiano S; Nagao T; Scott-Burden T; Vanhoutte PM
Circ Res; 1992 Jul; 71(1):137-44. PubMed ID: 1318793
[TBL] [Abstract][Full Text] [Related]
39. Femtomolar bradykinin-induced relaxation of isolated bovine coronary arteries, mediated by endothelium-derived nitric oxide.
Nakamura Y; Kawagoe K; Obi T; Miyamoto A; Ishiguro S; Nishio A
J Vet Pharmacol Ther; 1998 Aug; 21(4):304-8. PubMed ID: 9731953
[TBL] [Abstract][Full Text] [Related]
40. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors.
Auch-Schwelk W; Kuchenbuch C; Claus M; Walther B; Bossaller C; Friedel N; Graf K; Gräfe M; Fleck E
Eur Heart J; 1993 Nov; 14 Suppl I():154-60. PubMed ID: 8293767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
